{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:59:45Z","timestamp":1790805585258,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.esmoop.2025.105516","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:54:04Z","timestamp":1753995244000},"page":"105516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Neoadjuvant immunotherapy for nonmetastatic dMMR\/MSI colon cancer: a real-world retrospective AGEO study"],"prefix":"10.1016","volume":"10","author":[{"given":"C.","family":"Lemaire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boileve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Manceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Coutzac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Girot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lellouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Saltel-Fulero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lagorce-Pages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gallois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Karoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Palle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.105516_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2025.105516_bib2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.07.020","article-title":"Deficient mismatch repair\/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment","volume":"175","author":"Taieb","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105516_bib3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.20.01600","article-title":"Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials","volume":"39","author":"Cohen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105516_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105516_bib5","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.esmoop.2025.105516_bib6","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105516_bib7","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jamaoncol.2023.2761","article-title":"Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: a randomized clinical trial","volume":"9","author":"Ta\u00efeb","year":"2023","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105516_bib8","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105516_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2025.105516_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/JCO.2021.39.3_suppl.9","article-title":"Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study","volume":"39","author":"Andre","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105516_bib11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105516_bib12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1470-2045(21)00064-4","article-title":"Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial","volume":"22","author":"Andre","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2025.105516_bib13","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study","volume":"42","author":"Andre","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105516_bib14","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105516_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105516_bib16","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105516_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.023","article-title":"LBA31 Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: the NICHE-3 study","volume":"34","author":"Verschoor","year":"2023","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105516_bib18","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105516_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1200\/JCO.2025.43.4_suppl.241","article-title":"Assessment of pathologic response in the colorectal cancer cohort of the IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR\/MSI tumors","volume":"43","author":"Bibeau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105516_bib20","article-title":"NEOPRISM-CRC: neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR\/MSI-high colorectal cancer","volume":"40","author":"Shiu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105516_bib21","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105516_bib22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/SLA.0000000000003454","article-title":"Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22)","volume":"271","author":"Karoui","year":"2020","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105516_bib24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2004.11.017","article-title":"The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer","volume":"62","author":"Vecchio","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105516_bib25","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2025.105516_bib29","author":"Zarca"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105516_bib30","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/DCR.0000000000003290","article-title":"Neoadjuvant immunotherapy alone for patients with locally advanced and resectable metastatic colorectal cancer of dMMR\/MSI-H status","volume":"67","author":"Li","year":"2024","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.esmoop.2025.105516_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/acr-24-137","article-title":"Differential response to immunotherapy in different lesions of MSI-H double primary colorectal cancer: a case report and literature review","volume":"9","author":"Guo","year":"2024","journal-title":"AME Case Rep"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105516_bib32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/bjc.2016.211","article-title":"Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers","volume":"115","author":"Kim","year":"2016","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105516_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.fander.2021.09.101","article-title":"Granulomatoses associ\u00e9es aux immunoth\u00e9rapies du m\u00e9lanome","volume":"1","author":"Melin","year":"2021","journal-title":"Ann Dermatol V\u00e9n\u00e9r\u00e9ologie - FMC"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105516_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/CMR.0000000000000815","article-title":"Immunotherapy-induced granulomatous reaction in patients with melanoma","volume":"32","author":"Taskaynatan","year":"2022","journal-title":"Melanoma Res"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105516_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103698","article-title":"Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series","volume":"9","author":"Platt","year":"2024","journal-title":"ESMO Open"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925013857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925013857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:14:27Z","timestamp":1759612467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925013857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2059702925013857"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105516","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant immunotherapy for nonmetastatic dMMR\/MSI colon cancer: a real-world retrospective AGEO study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105516"}}